natgillin/translations-raw huggingface dataset:
Forty percent of the participants in Studies 1 and 2 completed the Psoriasis Symptom Diary©.
Štirideset odstotkov preiskovancev v 1. in 2. študiji je izpolnjevalo dnevnik simptomov psoriaze (Psoriasis Symptom Diary©).
Forty seven percent of patients had an identified complement regulatory factor mutation or auto- antibody.
Sedeminštirideset odstotkov bolnikov je imelo potrjeno mutacijo regulatornega faktorja komplementa ali avto-protitelo.
Forty-five of the patients in the studies were adults.
45 bolnikov v študijah je bilo odraslih.
Forty-five percent had an ECOG Performance Status of 1, 40% had elevated LDH and 23% had a BRAF mutated tumour.
Petinštirideset odstotkov bolnikov je imelo telesno zmogljivost 1 po ECOG, 40 % jih je imelo zvišan LDH in 23 % jih je imelo tumor z mutacijo BRAF.
Forty-nine patients were enrolled and received caspofungin at 50 mg/m2 IV once daily following a 70-mg/m2 loading dose on Day 1 (not to exceed 70 mg daily), of whom 48 were included in the MITT analysis.
Dobivali so kaspofungin, in sicer uvajalni odmerek 70 mg/m2 1. dan (a ne več kot 70 mg na dan) in nato 50 mg/m2 i.v. enkrat na dan; 48 bolnikov je bilo vključenih v analizo MITT.
Forty-one percent (41%) of patients treated with ONIVYDE across the clinical program were ≥ 65 years.
Enainštirideset odstotkov (41 %) bolnikov, zdravljenih z zdravilom ONIVYDE v kliničnem programu, je bilo starih ≥ 65 let.
Forty-six (57%) of the subjects were male; 66 (81%) were Caucasian.
46 oseb (57 %) je bilo moškega spola in 66 oseb (81 %) belcev.
Forty-six patients received a third course of LEMTRADA treatment at 12 mg/day or 24/mg day for 3 days at Month 24.
Šestinštirideset bolnikov je prejelo tretji cikel zdravljenja z odmerkom zdravila LEMTRADA 12 mg/dan ali 24/mg/dan 3 dni v 24. mesecu.
Forty-three patients 3 months to 21 years of age (median
Z efavirenzem se je zdravilo triinštirideset bolnikov, starih od 3 mesecev do 21 let (mediana 9,6 leta).
Forty-two (8%) experienced a serious adverse event associated with a decreased neutrophil count.
42 (8 %) je imelo resen neželen učinek, povezan z zmanjšanim številom nevtrofilcev.
Forty-two days after the booster dose, the seroprotection rate against both strains was 98.4%.
Dvainštirideset dni po obnovitvenem odmerku je bil delež serološke zaščite proti obema sevoma 98,4 %.
Forty-two percent of patients enrolled had both a CrCl < 70 mL/min and a comorbidity score of > 6.
42 % vključenih bolnikov je imelo hkrati očistek kreatinina < 70 ml/min in oceno komorbidnosti > 6.
Forxiga 10 mg film-coated tablets are yellow and diamond-shaped approximately 1.1 x 0.8 cm diagonally.
Tablete zdravila Forxiga 10 mg filmsko obložene tablete so rumene barve in rombaste oblike s približnimi diagonalami 1,1 x 0,8 cm.
Forxiga 5 mg film-coated tablets are yellow and round with diameter of 0.7 cm.
Tablete zdravila Forxiga 5 mg filmsko obložene tablete so rumene barve, okrogle oblike s premerom 0,7 cm.
Forxiga can also be used as an ‘add-on’ to other antidiabetes medicines, including insulin, when these medicines together with exercise and diet are not providing adequate control of the diabetes.
Zdravilo Forxiga se lahko uporablja tudi kot dodatek k drugim zdravilom za sladkorno bolezen, vključno z insulinom, kadar ti skupaj s telesno dejavnostjo in dieto ne omogočajo ustreznega nadzora nad sladkorno boleznijo.
Forxiga can be used on its own in patients whose blood glucose (sugar) levels are not satisfactorily controlled on diet and exercise alone and who cannot tolerate metformin (another antidiabetes medicine).
Zdravilo Forxiga se lahko uporablja kot samostojno zdravilo pri bolnikih, pri katerih zgolj dieta in telesna dejavnost ne zagotavljata ustreznega uravnavanja ravni glukoze (sladkorja) v krvi in pri katerih uporaba metformina (drugega antidiabetika) ni primerna zaradi intolerance.
Forxiga has not been studied in severe renal impairment (CrCl < 30 ml/min or eGFR < 30 ml/min/1.73 m2) or end-stage renal disease (ESRD).
Zdravilo Forxiga ni bilo raziskano pri hudi okvari ledvic (CrCl < 30 ml/min ali eGFR < 30 ml/min/1,73 m2) ali pri končni odpovedi ledvic (ESRD – end-stage renal disease).
Forxiga is a medicine that contains the active substance dapagliflozin.
Forxiga je zdravilo, ki vsebuje zdravilno učinkovino dapagliflozin.
Forxiga is not recommended for use in patients with moderate to severe renal impairment (patients with creatinine clearance [CrCl] < 60 ml/min or estimated glomerular filtration rate
Zdravila Forxiga ni priporočljivo uporabljati pri bolnikih z zmerno do hudo okvaro ledvic (bolnikih s kreatininskim očistkom [CrCl] < 60 ml/min ali z ocenjeno hitrostjo glomerulne filtracije
Forxiga is used if your diabetes cannot be controlled with other medicines for diabetes, diet and exercise.
Zdravilo Forxiga se uporablja, če vaše sladkorne bolezni ni mogoče urediti z drugimi zdravili proti sladkorni bolezni, z dieto in s telesno dejavnostjo.
Forxiga is used to treat adults with type 2 diabetes.
Zdravilo Forxiga se uporablja za zdravljenje odraslih s sladkorno boleznijo tipa 2.
Forxiga must not be used in people who are hypersensitive (allergic) to dapagliflozin or any of the other ingredients.
Zdravila Forxiga ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) dapagliflozin ali katero koli drugo sestavino zdravila.
Forxiga on its own has been compared with placebo (a dummy treatment) in two studies in 840 patients.
Zdravilo Forxiga so kot samostojno zdravilo primerjali s placebom (zdravilom brez zdravilne učinkovine) v dveh študijah na 840 bolnikih.
Fosamprenavir (1400 mg BID)
(1400 mg dvakrat na dan)
Fosamprenavir (1400 mg BID)
koncentracija amprenavirja se
Fosamprenavir (700 mg twice
fosamprenavir (700 mg dvakrat
Fosamprenavir (700 mg twice daily)
fosamprenavir (700 mg dvakrat
Fosamprenavir 1400 mg BID
1400 mg 2-krat na dan
fosamprenavir 700 mg and ritonavir 100 mg twice daily
fosamprenavir 700 mg in ritonavir 100 mg dvakrat na dan
Fosamprenavir 700 mg bid (saquinavir/ritonavir 1000/100 mg bid)
700 mg dvakrat na dan (sakvinavir/ritonavir 1000/100 mg dvakrat na dan)
Fosamprenavir 700 q12h 100 q12h Amprenavir ↑ 2.4 fold ↑ 11 fold Ritonavir increases the serum levels of amprenavir (from fosamprenavir) as a result of CYP3A4 inhibition.
700 na 12 ur 100 na 12 ur Amprenavir ↑ 2,4-krat ↑ 11-krat Ritonavir zavira CYP3A4 in tako zviša koncentracijo amprenavirja (iz fosamprenavirja) v serumu.
fosamprenavir and ritonavir lopinavir/ritonavir
fosamprenavir in ritonavir lopinavir/ritonavir
fosamprenavir, the dose of Vitekta
fosamprenavirjem mora biti
Fosamprenavir/
Maravirok
Fosamprenavir/ ritonavir (700/100 mg BID)
fosamprenavir/
Fosamprenavir/ ritonavir (700/100 mg BID)
Fosamprenavir/ ritonavir (700/100 mg dvakrat na dan)
Fosamprenavir/ ritonavir (700/100 mg BID)
tablete 400/100 mg
Fosamprenavir/ritona vir 700/100 mg BID
Fosamprenavir/ritona-vir 700/100 mg 2-krat na dan
Fosamprenavir/ritonavir
fosamprenavir/ritonavi
Fosamprenavir/ritonavir and Nevirapine Teva can be co- administered without dose adjustments
Fosamprenavir z ritonavirjem in zdravilo Nevirapin Teva se lahko uporablja sočasno brez prilagajanja odmerkov.
fosamprenavir/ritonavir and telaprevir (see
in telaprevirja ni priporočljiva (glejte
Fosamprenavir/ritonavir and Viramune can be co-administered without dose adjustments
Fosamprenavir z ritonavirjem in zdravilo Viramune lahko dajemo sočasno brez prilagajanja odmerkov.
Fosamprenavir/ritonavir decreases dolutegravir concentrations, but based on limited data, did not result in decreased efficacy in Phase III studies.
koncentracije dolutegravirja, vendar pa po omejenih podatkih v študijah 3. faze ni zmanjšal (njegove) učinkovitosti.
fosamprenavir/ritonavir is not
fosamprenavirja/ritonavirja ni
fosamprenavir/ritonavir may
prilagoditev odmerka
Fosamprenavir/ritonavir/Tenofovir disoproxil fumarate
fosamprenavir/ritonavir/dizoproksilte nofovirijev fumarat
Fosamprenavir/saquinavir/ efavirenz
indinavir/efavirenz
Fosamprenavir:
Maravirok:
Fosaprepitant pharmacokinetics has not been evaluated in special populations.
Pri posebnih skupinah bolnikov farmakokinetike fosaprepitanta niso proučevali.
FOSAVANCE 70 mg/2,800 IU tablets
FOSAVANCE 70 mg/2.800 i.e. tablete alendronska kislina/holekalciferol
FOSAVANCE 70 mg/2,800 IU tablets Alendronic acid /colecalciferol
FOSAVANCE 70 mg/2.800 i.e. tablete alendronska kislina/holekalciferol
FOSAVANCE 70 mg/2,800 IU tablets are available as capsule-shaped, white to off-white tablets marked with an outline of a bone image on one side and ‘710’ on the other.
FOSAVANCE 70 mg/2.800 i.e. tablete imajo obliko kapsule, so bele do skoraj bele barve, na eni strani imajo vtisnjen obris kosti, na drugi pa oznako ‘710’.
FOSAVANCE 70 mg/5,600 IU tablets
FOSAVANCE 70 mg/5.600 i.e. tablete alendronska kislina/holekalciferol
FOSAVANCE 70 mg/5,600 IU tablets Alendronic acid /colecalciferol
FOSAVANCE 70 mg/5.600 i.e. tablete alendronska kislina/holekalciferol
FOSAVANCE 70 mg/5,600 IU tablets are available as modified rectangle-shaped, white to off-white tablets marked with an outline of a bone image on one side and ‘270’ on the other.
FOSAVANCE 70 mg/5.600 i.e. tablete so pravokotniku podobne oblike, bele do skoraj bele barve, na eni strani imajo vtisnjen obris kosti, na drugi pa oznako ‘270’.
FOSAVANCE contains lactose and sucrose.
Zdravilo FOSAVANCE vsebuje laktozo in saharozo.
FOSAVANCE is a combination tablet containing the two active substances alendronate sodium trihydrate and colecalciferol (vitamin D3).
Zdravilo FOSAVANCE je kombinirana tableta, ki vsebuje dve zdravilni učinkovini natrijev alendronat trihidrat in holekalciferol (vitamin D3).
FOSAVANCE is a tablet containing the two active substances, alendronic acid (commonly called alendronate) and colecalciferol known as vitamin D3.
FOSAVANCE je tableta, ki vsebuje dve zdravilni učinkovini: alendronsko kislino (splošno poimenovano alendronat) in holekalciferol oziroma vitamin D3.
FOSAVANCE is available in packs containing 2, 4, 6 or 12 tablets.
Zdravilo FOSAVANCE je na voljo v pakiranjih, ki vsebujejo 2, 4, 6 ali 12 tablet.
FOSAVANCE is available in packs containing2, 4 or 12 tablets.
Zdravilo FOSAVANCE je na voljo v pakiranjih, ki vsebujejo 2, 4 ali 12 tablet.
FOSAVANCE is indicated for the treatment of postmenopausal osteoporosis in women at risk of vitamin D insufficiency.
Zdravilo FOSAVANCE je indicirano za zdravljenje pomenopavzalne osteoporoze pri ženskah s tveganjem za pomanjkanje vitamina D.
FOSAVANCE is indicated for the treatment of postmenopausal osteoporosis in women who are not receiving vitamin D supplementation and are at risk of vitamin D insufficiency.
Zdravilo FOSAVANCE je indicirano za zdravljenje pomenopavzalne osteoporoze pri ženskah, ki ne prejemajo dodatka vitamina D in imajo tveganje za pomanjkanje vitamina D.
FOSAVANCE is not recommended for patients with renal impairment where creatinine clearance is less than 35 ml/min, due to lack of experience.
Bolnikom z ledvično okvaro, pri katerih je kreatininski očistek manjši od 35 ml/min, zdravila FOSAVANCE zaradi pomanjkanja izkušenj ne priporočamo.
FOSAVANCE may have a moderate influence on the ability to drive and use machines in patients that experience certain adverse reactions (for example blurred vision, dizziness and severe bone muscle or joint pain (see section 4.8)).
Zdravilo FOSAVANCE ima lahko pri bolnikih, pri katerih se pojavijo določeni neželeni učinki (npr. zamegljen vid, omotica in hude bolečine v kosteh, mišicah ali sklepih (glejte poglavje 4.8)), zmeren vpliv na sposobnost vožnje in upravljanja s stroji.
FOSAVANCE reduces the risk of vertebral and hip fractures.
Zdravilo FOSAVANCE zmanjša tveganje za vertebralne zlome in za zlome kolka.
FOSAVANCE should not be given to children and adolescents less than 18 years of age.
Zdravila FOSAVANCE se ne sme dajati otrokom in mladostnikom, mlajšim od 18 let.
FOSAVANCE should not be taken at bedtime or before arising for the day.
Bolnik zdravila FOSAVANCE ne sme vzeti pred spanjem ali preden zjutraj vstane.
FOSAVANCE should not be used in children less than 18 years of age because no data are available for the alendronic acid/colecalciferol combination.
Ker podatkov o uporabi kombinacije alendronske kisline/holekalciferola ni na voljo, otroci, mlajši od 18 let, zdravila FOSAVANCE ne smejo jemati.
FOSAVANCE should only be swallowed after getting up for the day with a full glass of water (not less than 200 ml).
Bolnik mora zdravilo FOSAVANCE pogoltniti zjutraj, ko vstane, s polnim kozarcem vode (ne manj kot 200 ml).
FOSAVANCE with food and drink
Zdravilo FOSAVANCE skupaj s hrano in pijačo
Foscan 1 mg/ml solution for injection Temoporfin
FOSCAN 1 mg/ml raztopina za injiciranje temoporfin
Foscan will make you sensitive to light for about 15 days after your injection.
Po injiciranju zdravila Foscan boste preobčutljivi za svetlobo za približno 15 dni.
foscarnet (for viral infection)
foskarnet (za virusno okužbo)
foscarnet (for viral infection) adefovir (for HBV infection)
foskarnet (za virusne okužbe) adefovir (za okužbe z virusom HBV)
foscarnet (for viral infection).
foskarnet (za virusno okužbo).
foscarnet, cidofovir or tenofovir disoproxil fumarate, for viral infections pentamidine, for other types of infection.
foskarnet, cidofovir ali dizoproksiltenofovirat fumarat proti virusnim okužbam; pentamidin proti drugim vrstam okužb.
foscarnet, ganciclovir, cidofovir (for viral infections) amphotericin B, pentamidine (for fungal infections)
foskarnet, ganciklovir, cidofovir (za virusne okužbe) amfotericin B, pentamidin (za glivične okužbe)
foscarnet, ganciclovir, cidofovir (for viral infections) amphotericin B, pentamidine (for fungal infections)
foskarnet, ganciklovir, cidofovir (za virusno okužbo) amfotericin B, pentamidin (za glivično okužbo)
foscarnet, ganciclovir, cidofovir (medicines for viral infections) amphotericin B, pentamidine (medicines for fungal infections)
foskarnet, ganciklovir, cidofovir (zdravila proti virusnim okužbam), amfotericin B, pentamidin (zdravila proti glivičnim okužbam),
foscarnet, ganciclovir, or cidofovir (for viral infection),
foskarnet, ganciklovir ali cidofovir (za virusno okužbo);
Fosveset
fasoveset
Four 200 mg capsules (800 mg) - taken three times a day (every 8 hours).
Štiri 200 mg kapsule (800 mg) - vzete trikrat na dan (vsakih 8 ur).
four 25 mg tablets twice daily or one 100 mg tablet twice daily
štiri 25 mg tablet dvakrat na dan ali ena 100 mg tableta dvakrat na dan
Four 320 mg/40 mg tablets a day
Štiri 320 mg/40 mg tablete na dan
Four 5 mg tablets once a day
Štiri 5 mg tablete enkrat dnevno
Four case reports (2 published) with very suggestive causal association were issued during the reporting period regarding rhabdomyolysis in association with levetiracetam use.
Med obdobjem poročanja so bila izdana 4 poročila o primerih (2 objavljena), ki močno nakazujejo na vzročno povezavo rabdomiolize in uporabe levetiracetama.
Four days after your injection, your doctor will treat your cancer with laser light.
Zdravnik bo 4 dni po injekciji z lasersko svetlobo zdravil vašega raka.
Four different schedules have been studied (6-10-14 weeks, 2-4-6 months; 3-4-5 months and 3-4½-6 months) according to routine vaccination practices in different countries with three doses administered within the first six months of life.
Glede na rutinsko prakso cepljenja v različnih državah so bile raziskane štiri različne sheme z dajanjem treh odmerkov v prvih šestih mesecih starosti (6-10-14 tednov, 2-4-6 mesecev; 3-4- 5 mesecev in 3-41/2-6 mesecev).
Four embryo-fetal development studies were performed in rabbits covering doses of 200, 600, 800, 1200 and 1800 mg/kg/day.
Štiri študije embrio-fetalnega razvoja pri kuncih so izvedli z odmerki 200, 600, 800, 1200 in
Four embryo-foetal development studies were performed in rabbits covering doses of 200, 600, 800, 1,200 and 1,800 mg/kg/day.
Štiri študije embrio-fetalnega razvoja pri kuncih so izvedli pri odmerkih 200, 600, 800, 1200 in 1800 mg/kg/dan.
Four embryo-foetal development studies were performed in rabbits covering doses of 200, 600, 800, 1200 and 1800 mg /kg/day.
Štiri študije embriofetalnega razvoja pri kuncih so izvedli z odmerki 200, 600, 800, 1.200 in
Four embryo-foetal development studies were performed in rabbits covering doses of 200, 600, 800, 1200 and 1800 mg/kg/day.
Štiri študije embriofetalnega razvoja pri kuncih so izvedli z odmerki 200, 600, 800, 1200 in
four MIRAPEXIN 0.26 mg prolonged-release tablets.
štiri MIRAPEXIN 0,26 mg tablete s podaljšanim sproščanjem
Four multicenter studies with either Pravafenix 40 mg/160 mg or Pravastatin 40 mg or Simvastatin 20 mg were conducted: 3 studies included a 12 week randomized, double-blind, active controlled period with an open-label extension phase and one was a 24-week open-label study.
Narejene so bile štiri multicentrične študije z zdravilom Pravafenix 40 mg/160 mg ali s pravastatinom 40 mg ali s simvastatinom 20 mg: 3 študije so vključevale 12-tedensko randomizirano, dvojno slepo, aktivno nadzorovano študijo z odprto podaljšano fazo, ena pa je bila 24-tedenska odprta študija.
Four multicentre, double-blind, placebo-controlled obesity Phase 3 studies (NB-301, NB-302, NB-303 and NB-304) were conducted to evaluate the effect of naltrexone / bupropion in conjunction with lifestyle modification in 4,536 subjects randomised to naltrexone/bupropion or placebo.
Izvedli so štiri multicentrične, dvojno slepe, s placebom nadzorovane študije 3. faze glede debelosti (NB-301, NB-302, NB-303 in NB-304) za ovrednotenje učinkov kombinacije naltrekson/bupropion v povezavi s spremembo načina življenja pri 4.536 preiskovancih, randomiziranih na uporabo naltreksona/bupropiona ali placeba.
Four of these seven GIST patients discontinued treatment following first observation of DVT.
Pri štirih od teh sedmih bolnikov z GIST so zdravljenje prekinili po prvih znakih globoke venske tromboze.
four Oprymea 0.26 mg prolonged-release tablets.
Tri Oprymea 0,26 mg tablete s podaljšanim sproščanjem
Four or more NRTI- associated mutations
Štiri ali več mutacij, povezanih z NRTI
Four other studies compared Edistride with placebo, when used as an add-on to either metformin, a sulphonylurea (glimepiride), a thiazolidinedione or insulin in 2,370 patients.
Zdravilo Edistride so primerjali s placebom v štirih drugih študijah, v katerih je 2 370 bolnikov zdravilo prejemalo kot dodatek k metforminu, sulfonilsečnini (glimepiridu), tiazolidindionu ali insulinu.
Four other studies compared Forxiga with placebo, when used as an add-on to either metformin, a sulphonylurea (glimepiride), a thiazolidinedione or insulin in 2,370 patients.
Zdravilo Forxiga so primerjali s placebom v štirih drugih študijah, v katerih je 2 370 bolnikov zdravilo prejemalo kot dodatek k metforminu, sulfonilsečnini (glimepiridu), tiazolidindionu ali insulinu.
Four patients with severe renal impairment (creatinine clearance 12 to 30 mL/min) were included in the data set.
Podatki vključujejo tudi podatke štirih bolnikov s hudo ledvično okvaro (očistek kreatinina 12 do 30ml/min).
Four placebo-controlled phase III studies in plaque psoriasis were pooled to evaluate the safety of Cosentyx in comparison to placebo up to 12 weeks after treatment initiation.
Za oceno varnosti uporabe zdravila Cosentyx v primerjavi s placebom v obdobju do 12 tednov po začetku zdravljenja so združili podatke štirih s placebom kontroliranih študij faze III, v katerih so proučevali psoriazo s plaki.
four pump actuations
štirje pritiski navzdol
Four randomized controlled studies were performed in dialysis patients currently treated with darbepoetin alfa or epoetin at the time of enrollment.
Pri dializnih bolnikih, ki so se v času vključevanja v raziskavo zdravili z darbepoetinom alfa ali epoetinom alfa, so opravili štiri randomizirane kontrolirane klinične raziskave.
Four randomized controlled studies were performed in dialysis patients currently treated with darbepoetin alfa or epoetin at the time of enrollment.
Pri dializnih bolnikih, ki so se v času vključevanja v raziskavo zdravili z darboepoetinom alfa ali epoetinom, so opravili štiri randomizirane kontrolirane klinične raziskave.
Four randomized controlled studies were performed in dialysis patients currently treated with darbepoetin alfa or epoetin at the time of enrollment.
Pri dializnih bolnikih, ki so se v času vključevanja v raziskavo zdravili z darboepoetinom ali epoetinom, so opravili štiri randomizirane kontrolirane klinične raziskave.
Four ritonavir metabolites have been identified in man.
Odmerna shema ritonavirja
four SIFROL 0.26 mg prolonged-release tablets.
štiri SIFROL 0,26 mg tablete s podaljšanim sproščanjem
Four single-arm, uncontrolled, open-label Phase II clinical studies were conducted to determine the safety and efficacy of dasatinib in patients with CML in chronic, accelerated, or myeloid blast phase, who were either resistant or intolerant to imatinib.
Za določitev varnosti in učinkovitosti dasatiniba pri bolnikih s KML v kroničnem obdobju, obdobju pospešenega poteka ali obdobju mieloblastne preobrazbe, ki se na zdravljenje z imatinibom niso odzvali ali ga niso prenašali, so bile izvedene štiri enoskupinske (“single-arm”), nenadzorovane, odprte klinične študije II. faze.
Four studies have evaluated the effects of pertuzumab on the PK of co-administered cytotoxic agents, docetaxel, gemcitabine, erlotinib and capecitabine.
Štiri študije so ocenjevale vpliv pertuzumaba na farmakokinetiko sočasno danih citotoksičnih zdravil: docetaksela, gemcitabina, erlotiniba in kapecitabina.
Four studies of ACOMPLIA in overweight and obese patients were carried out, involving almost 7,000 patients, whose weight at the start of the studies was on average 94 to 104 kg.
Zdravilo ACOMPLIA je bilo raziskano v štirih študijah, v katerih je sodelovalo skoraj 7000 debelih bolnikov in bolnikov s čezmerno telesno maso, katerih teža je bila na začetku študij povprečno med 94 in 104 kg.
Four studies of ZIMULTI in overweight and obese patients were carried out, involving almost 7,000 patients, whose weight at the start of the studies was on average 94 to 104 kg.
Zdravilo ZIMULTI je bilo raziskano v štirih študijah, v katerih je sodelovalo skoraj 7000 debelih bolnikov in bolnikov s čezmerno telesno maso, katerih teža je bila na začetku študij povprečno med 94 in 104 kg.
Four subjects had virologic failure none of which had INI resistance at the time of virologic failure.
Štiri osebe so imele virusni neodziv, nobena od teh pa ob času virusnega neodziva ni imela odpornosti na INI.
Four thousand six hundred and twenty eight (4,628) patients were randomised and treated for up to 30 months maximum (median follow-up: 22 months) with either dronedarone 400 mg twice daily (2,301 patients) or placebo (2,327 patients), in addition to conventional therapy including beta-blockers (71%), ACE inhibitors or AIIRAs (69%) digitalis (14%), calcium antagonists (14%), statins (39%), oral anticoagulants (60%), chronic antiplatelet therapy (6%) and/or diuretics (54%).
Randomiziranih je bilo 4628 bolnikov, ki so bili zdravljeni do največ 30 mesecev (mediano spremljanje: 22 mesecev) bodisi z dronedaronom 400 mg dvakrat na dan (2301 bolnik) ali placebom (2327 bolnikov), in sicer poleg konvencionalnega zdravljenja, ki je vključevalo zaviralce beta (71 %), zaviralce ACE ali antagoniste receptorjev angiotenzina II (69 %), digitalis (14 %), kalcijeve antagoniste (14 %), statine (39 %), peroralne antikoagulanse (60 %), kronično antiagregacijsko zdravljenje (6 %) in/ali diuretike (54 %).
Four treatment cycles of this combination are administered.
Bolnik prejme štiri kroge kombiniranega zdravljenja.
Four treatment cycles of this combination therapy are administered.
Bolnik prejme štiri kroge zdravljenja z zdravilom Bortezomib Accord
Four treatment cycles of this combination therapy are administered.
Bolnik prejme štiri kroge zdravljenja z zdravilom Bortezomib Hospira
Four treatment cycles of this combination therapy are administered.
Bolnik prejme štiri kroge zdravljenja z zdravilom VELCADE.